Copenhagen, 2016-07-11 15:14 CEST (GLOBE NEWSWIRE) -- With reference to QIAGEN N.V.’ announcement of 6 July 2016 regarding the call for redemption of minority shareholders in Exiqon A/S, subsequent of which QIAGEN N.V. will hold all outstanding shares in Exiqon, which are not treasury shares, the board of directors of Exiqon has today decided to request Nasdaq Copenhagen A/S for a cancellation from trading and delisting of all shares in Exiqon A/S from Nasdaq Copenhagen A/S. In case Nasdaq Copenhagen accepts the request, the last day of trading is expected to be 3 August 2016.
Additional information
Lars Kongsbak, CEO, phone +45 4566 0888 (cell: +45 4090 2101)
About Exiqon
At Exiqon, we advance the research of when and where genes are expressed. We empower scientists across the world with best-in-class products and user-friendly business solutions designed to transform workflows in our industry. Exiqon operates in two business areas: Exiqon Life Sciences is a leading provider of flexible solutions for gene expression analysis. Academia, biotech and pharmaceutical companies around the world use Exiqon’s research products to make ground-breaking discoveries. Exiqon Diagnostics collaborates with diagnostic and pharmaceutical companies to develop novel molecular diagnostic tests for early detection of diseases, which can help physicians make better treatment decisions. Exiqon is listed on Nasdaq Copenhagen. For more information about us, please visit www.exiqon.com